Charles River Laboratories International, Inc.'s next confirmed earnings release is scheduled for February 24, 2027.
| Earnings Date | 2/24/2027 |
As of September 30, 2026, Charles River Laboratories International, Inc. has 47.88M shares outstanding.
| Shares Outstanding | 47.88M |
As of September 30, 2026, Charles River Laboratories International, Inc. maintains a current ratio of 1.41, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 86.98, indicating elevated leverage, while an interest coverage ratio of 4.06 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.41 |
| Quick Ratio | 0.86 |
| Debt / Equity | 86.98 |
| Debt / EBITDA | 6.42 |
| Interest Coverage | 4.06 |
Over the twelve months ended September 30, 2026, Charles River Laboratories International, Inc. posted a return on equity (ROE) of 1.21, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.54, measuring how efficiently the asset base is converted into earnings. The company generates approximately 3.65M in revenue per employee across its workforce of 19,700.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.52 indicates how many times Charles River Laboratories International, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 1.21 |
| Return on Assets (ROA) | 0.54 |
| Revenue Per Employee | 3.65M |
| Employee Count | 19,700.00 |
| Inventory Turnover | 8.52 |
Over the twelve months ended September 30, 2026, Charles River Laboratories International, Inc. recorded an income tax benefit of -2.58B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.81B and 725.66M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -2.58B |
As of the close on October 23, 2026, Charles River Laboratories International, Inc.'s stock has gained approximately 58.61% over the past 52 weeks.
| 52-Week Price Change | 58.61% |
Over the twelve months ended September 30, 2026, Charles River Laboratories International, Inc. generated 71.81B in revenue and converted that into 725.66M in net income, yielding earnings per share of 15.79. EBITDA reached 8.02B, while operating income came in at 9.66B.
| Revenue | 71.81B |
| Gross Profit | 23.94B |
| Operating Income | 9.66B |
| Pretax Income | -1.81B |
| Net Income | 725.66M |
| EBITDA | 8.02B |
| EBIT | 2.87B |
| Earnings Per Share (EPS) | 15.79 |
As of September 30, 2026, Charles River Laboratories International, Inc. holds 3.62B in cash and equivalents against 51.44B in total debt, resulting in a net debt position of 40.35B. Total book value stands at 58.27B, with working capital of 8.05B providing operational flexibility.
| Cash & Cash Equivalents | 3.62B |
| Total Debt | 51.44B |
| Net Debt | 40.35B |
| Equity (Book Value) | 58.27B |
| Book Value Per Share | 1,217.11 |
| Working Capital | 8.05B |
Charles River Laboratories International, Inc. produced 11.24B in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | 11.24B |
| Free Cash Flow | 11.24B |
| FCF Per Share | 231.74 |
Over the twelve months ended September 30, 2026, Charles River Laboratories International, Inc. posted a gross margin of 33.33, reflecting its pricing power and cost economics. The operating margin of 13.45 and net profit margin of 1.01 provide insight into operational efficiency.
| Gross Margin | 33.33 |
| Operating Margin | 13.45 |
| Pretax Margin | -2.52 |
| Profit Margin | 1.01 |
| EBITDA Margin | 11.16 |